Anti-HER2 imaging agents for breast cancer imaging
| Autor: | K Vigor, A Plueckthun, B Tolner, K Chester, Stephen J. Mather, Gregory P. Adams, Matthew K. Robinson |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
biology
business.industry Disease medicine.disease Bioinformatics Breast cancer Surgical oncology Cell surface receptor Poster Presentation medicine Cancer research biology.protein Epidermal growth factor receptor Anti her2 skin and connective tissue diseases business neoplasms Tyrosine kinase Subclinical infection |
| Zdroj: | Breast Cancer Research : BCR |
| ISSN: | 1465-542X |
| DOI: | 10.1186/bcr2539 |
| Popis: | Overexpression of human epidermal growth factor receptor 2 (HER2) tyrosine kinase cell surface receptor occurs in 25 to 30% of all breast cancer and is linked to aggressive phenotype and high-mortality disease. HER2 is a clinically important target in diagnosis and treatment of breast cancer but despite its pivotal role there are no established tools for quantitative clinical imaging of the extent and location of HER2-positive (HER2+) tumours in patients. Such a tool could provide important clinical diagnostic information by early detection of subclinical HER2+ disease, optimal management of current anti-HER2 therapies and response assessment of novel therapeutics. We aimed to generate recombinant proteins that would achieve sensitive and specific detection of HER2+ tumours in the clinic using radioimmunoimaging. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink